Claims
- 1. A method of producing activated T cells directed toward hepsin, comprising the steps of:exposing dendritic cells to a hepsin fragment consisting of the amino acid sequence of SEQ ID NO. 28 or 148, thereby producing activated dendritic cells; exposing said activated dendritic cells to T cells, wherein said activated dendritic cells would present said hepsin fragment to said T cells, thereby producing activated T cells directed toward said hepsin fragment.
- 2. The method of claim 1, wherein said dendritic cells, which are isolated from an individual prior to said exposure to said hepsin fragment, are reintroduced into said individual subsequent to said exposure to said hepsin fragment.
CROSS-REFERENCE TO RELATED APPLICATIONS
This is a continuation-in-part application which claims the benefit of priority under 35 USC §120 of U.S. Ser. No. 09/861,966, filed May 21, 2001, now U.S. Pat. No. 6,518,028, which is a divisional application of U.S. Ser. No. 09/510,738, now U.S. Pat. No. 6,268,165, which claims the benefit of priority under 35 USC §120 of U.S. Ser. No. 09/039,211, filed Mar. 14, 1998, which claims benefit of provisional patent application U.S. Ser. No. 60/041,404, filed Mar. 19, 1997, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
6232456 |
Cohen et al. |
May 2001 |
B1 |
Non-Patent Literature Citations (3)
Entry |
Paglia et al. Murine Dendritic Cells Loaded in Vitro with Soluble Protein Prime Cytotoxic T Lymphocytes against Tumor Antigen in Vivo. J. Exp. Med 183:317-322, Jan. 1996.* |
Jain. Barriers to Drug Deleiver in Solid Tumors. Scientific American 271(1): 58-65, 1994.* |
Gura. System for Identifying New Drugs are Often Faulty. Scienc 278: 1041 and 1042, Nov. 7, 1997. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/041404 |
Mar 1997 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09/861966 |
May 2001 |
US |
Child |
09/919048 |
|
US |